A new weight loss pill is expanding the pharmaceutical leader's already massive market opportunity.

Eli Lilly (LLY) has cemented its status as the world's leading pharmaceutical company as it produced a stellar set of Q1 2026 ...

Lilly hiked its full-year sales outlook by $2 billion, and also raised its adjusted profit guidance.

Learn more Eli Lilly raised its full-year 2026 revenue guidance to between $82 billion and $85 billion after first-quarter ...

Eli Lilly said its tirzepatide franchise had another stellar quarter.

Eli Lilly beats Q1 estimates and raises 2026 revenue outlook to $82–$85 billion. Mounjaro and Zepbound drive strong sales ...

Eli Lilly shares jumped after the drugmaker posted earnings that topped estimates and hiked its outlook, thanks to booming ...

Blockbuster sales of its flagship GLP-1 treatments have propelled Eli Lilly And Co.‘s first-quarter earnings, prompting a prominent Wall Street analyst to defend the stock’s valuation and highlight ...

Discover how Eli Lilly is increasing medical weight loss access in Indiana through Zepbound vials. Learn how this Indy ...

Eli Lilly (NYSE: LLY) has established itself as the leader in the weight-loss drug market. Since this area is projected to ...

Eli Lilly's weight loss pill launch has been closely watched after the successful start of Novo Nordisk's Wegovy pill.